The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 12, 2012, Pages 1386-1396

  Solomon, D ^a   Yarlas, A ^b   Hodgkins, P ^a   Karlstadt, R ^a   Yen, L ^a   Kane, S ^c  

^a SHIRE   (United States)

^b QualityMetric Incorporated   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ABDOMINAL DISTENSION; ADULT; ARTICLE; CONTROLLED STUDY; DEFECATION HABIT; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OPEN STUDY; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RECTUM HEMORRHAGE; SENSITIVITY ANALYSIS; SHORT INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; TREATMENT DURATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADULT; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861183245     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05107.x     Document Type: Article

References (38)

1. Bernklev T, Jahnsen J, Aadland E, et al,. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand J Gastroenterol 2004; 39: 365-73. (Pubitemid 38526725)
2. Casellas F, Arenas JI, Baudet JS, et al,. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005; 11: 488-96. (Pubitemid 40704084)
3. Han SW, McColl E, Barton JR, James P, Steen IN, Welfare MR,. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis 2005; 11: 24-34. (Pubitemid 40340253)
4. Janke KH, Klump B, Gregor M, Meisner C, Haeuser W,. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 272-86. (Pubitemid 40439682)
5. Larsson K, Loof L, Ronnblom A, Nordin K,. Quality of life for patients with exacerbation in inflammatory bowel disease and how they cope with disease activity. J Psychosom Res 2008; 64: 139-48.
6. Lix LM, Graff LA, Walker JR, et al,. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1575-84.
7. McColl E, Han SW, Barton JR, Welfare MR,. A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis. Qual Life Res 2004; 13: 805-11. (Pubitemid 38509980)
8. Mokrowiecka A, Jurek K, Pinkowski D, Malecka-Panas E,. The comparison of Health-Related Quality of Life (HRQL) in patients with GERD, peptic ulcer disease and ulcerative colitis. Adv Med Sci 2006; 51: 142-7.
9. Irvine EJ,. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2008; 14: 554-65. (Pubitemid 351571837)
10. Feagan BG, Reinisch W, Rutgeerts P, et al,. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794-802. (Pubitemid 46496629)
11. Reinisch W, Sandborn WJ, Bala M, et al,. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13: 1135-40. (Pubitemid 47402598)
12. Irvine EJ, Yeh CH, Ramsey D, Stirling AL, Higgins PD,. The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis. Aliment Pharmacol Ther 2008; 28: 1278-86.
13. Zahn A, Hinz U, Karner M, Ehehalt R, Stremmel W,. Health-related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis. Inflamm Bowel Dis 2006; 12: 1058-67. (Pubitemid 44665476)
14. Hjortswang H, Jarnerot G, Curman B, et al,. Validation of the inflammatory bowel disease questionnaire in Swedish patients with ulcerative colitis. Scand J Gastroenterol 2001; 36: 77-85. (Pubitemid 32147185)
15. Reinisch W, Sandborn WJ, Rutgeerts P, et al,. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012; 18: 201-11.
16. Carter MJ, Lobo AJ, Travis SP,. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53: V1-16. (Pubitemid 39120096)
17. Cohen RD, Woseth DM, Thisted RA, Hanauer SB,. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95: 1263-76. (Pubitemid 30263523)
18. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 1371-85. (Pubitemid 39062279)
19. Marshall JK, Irvine EJ,. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000; 95: 1628-36. (Pubitemid 30484995)
20. Kamm MA, Sandborn WJ, Gassull M, et al,. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75. (Pubitemid 46108735)
21. Lichtenstein GR, Kamm MA, Boddu P, et al,. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5: 95-102. (Pubitemid 46096842)
22. Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M,. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005; 11: 421-7. (Pubitemid 40704075)
23. Kamm MA, Lichtenstein GR, Sandborn WJ, et al,. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57: 893-902. (Pubitemid 351919522)
24. Irvine EJ, Zhou Q, Thompson AK,. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996; 91: 1571-8. (Pubitemid 26269173)
25. Kane S, Katz S, Jamal MM, et al,. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX® mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflamm Bowel Dis 2011 [Epub ahead of print].
26. Han SW, Gregory W, Nylander D, et al,. The SIBDQ: further validation in ulcerative colitis patients. Am J Gastroenterol 2000; 95: 145-51. (Pubitemid 30041550)
27. Jowett SL, Seal CJ, Barton JR, Welfare MR,. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol 2001; 96: 2921-8. (Pubitemid 32959534)
28. Lam MY, Lee H, Bright R, Korzenik JR, Sands BE,. Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire. Inflamm Bowel Dis 2009; 15: 599-607.
29. Schroeder KW, Tremaine WJ, Ilstrup DM,. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9. (Pubitemid 18010466)
30. Sutherland LR, Martin F, Greer S, et al,. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894-8. (Pubitemid 17072238)
31. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH,. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008; 14: 1660-6.
32. Fayers PM, King MT,. How to guarantee finding a statistically significant difference: the use and abuse of subgroup analyses. Qual Life Res 2009; 18: 527-30.
33. Kane S, Solomon D, Palmen M, Barrett K,. Long-term use of MMX® mesalazine 2.4 g/day is well tolerated in patients with quiescent ulcerative colitis. J Gastroenterol Hepatol 2010; 25: A91.
34. Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE,. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007; 26: 205-15. (Pubitemid 46985493)
35. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M,. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971-6.
36. Dhanda AD, Creed TJ, Greenwood R, Sands BE, Probert CS,. Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials? Inflamm Bowel Dis 2012 [Epub ahead of print].
37. Higgins PD, Schwartz M, Mapili J, Zimmermann EM,. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol 2005; 100: 355-61. (Pubitemid 40314520)
38. Baars JE, Nuij VJ, Oldenburg B, Kuipers EJ, van der Woude CJ,. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 2011 [Epub ahead of print].